Simon S. Yu

Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.

P. Mandal, Jason P. Burke, F. Mseeh, 2021, Journal of medicinal chemistry.

Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor.

P. Mandal, Jason P. Burke, F. Mseeh, 2021, Journal of medicinal chemistry.

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Justin K. Huang, P. Mandal, Jason P. Burke, 2020, Cancer Research.

Discovery of IACS-9439, a potent, exquisitely selective and orally bioavailable inhibitor of CSF1R.

P. Mandal, Jason P. Burke, F. Mseeh, 2020, Journal of medicinal chemistry.

Abstract 3277: IACS-9779, a development candidate that inhibits 2,3-dioxygenase (IDO) activity by blocking heme incorporation into IDO apoenzyme

F. Mseeh, T. Heffernan, Ningping Feng, 2019, Clinical Research (Excluding Clinical Trials).